Precision medicine arriving for AML patients in China

25 February 2022

GlobalData has taken a look at the acute myeloid leukemia (AML) treatment landscape in China.

The data and analytics company has reviewed the market following China’s approval of CStone Pharmaceuticals’ (HKG: 2616) Tibsovo (ivosidenib tablets) to treat adults with relapsed/refractory AML with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, providing a new precision therapy for this patient population.

"China has a dominant visibility in the precision medicine field backed by continued government vision and funding"With multiple precision therapies now available, the cancer treatment arsenal is expanding for AML patients in the country, says GlobalData.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK